Want to see GLUE full AI Analyst Report?
Monte Rosa Therapeutics (GLUE) Ownership - Who Owns Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) Ownership Overview
- 8.88% Insiders
- 17.37% Mutual Funds
- 0.31% Other Institutional Investors
- 15.64% ETFs
- 57.80% Public Companies and Individual Investors
The ownership structure of Monte Rosa Therapeutics (GLUE) stock is a mix of institutional, retail, and individual investors. Approximately 33.33% of the company’s stock is owned by Institutional Investors, 8.88% is owned by Insiders, and 57.80% is owned by Public Companies and Individual Investors.
The ownership structure of Monte Rosa Therapeutics (GLUE) stock is a mix of institutional, retail, and individual investors. Approximately 33.33% of the company’s stock is owned by Institutional Investors, 8.88% is owned by Insiders, and 57.80% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jul 16, 2026 | Warmuth Markus | $220,210 | |
| Jun 29, 2026 | Anthony M. Manning | $231,100 | |
| May 21, 2026 | Anthony M. Manning | $180,100 | |
| Apr 14, 2026 | Warmuth Markus | $141,120 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Fisher Asset Management Llc | $8,797,184 | |
| Jun 30, 2026 | Woodline Partners Lp | $23,301,793 | |
| Jun 30, 2026 | Duquesne Family Office Llc | $7,201,920 | |
| Jun 30, 2026 | $165,602,705 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 6,843,087 | Institution | 8.02% | 73,631,616 |
| Ali Behbahani | 6,692,298 | Insider | 7.84% | 72,009,126 |
| Felix Baker | 4,345,736 | Institution | 5.09% | 46,760,119 |
| Vanguard | 4,072,686 | Institution | 4.77% | 43,822,101 |
| Ishares | 3,583,942 | Institution | 4.20% | 38,563,216 |
| Vanguard Index Funds | 3,335,838 | Institution | 3.91% | 35,893,617 |
| Brad Bolzon | 3,180,780 | Institution | 3.73% | 34,225,193 |
| Spdr | 2,472,443 | Institution | 2.90% | 26,603,487 |
| T. Rowe Price New Horizons Fund, Inc. | 2,232,091 | Institution | 2.62% | 24,017,299 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,823,210 | Institution | 2.14% | 19,617,740 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 3,335,838 | Institution | 3.91% | 35,893,617 |
| T. Rowe Price New Horizons Fund, Inc. | 2,232,091 | Institution | 2.62% | 24,017,299 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,823,210 | Institution | 2.14% | 19,617,740 |
| T. Rowe Price Integrated Equity Funds, Inc. | 1,538,053 | Institution | 1.80% | 16,549,450 |
| Fidelity Salem Street Trust | 889,302 | Institution | 1.04% | 9,568,890 |
| Fidelity Concord Street Trust | 844,617 | Institution | 0.99% | 9,088,079 |
| Dfa Investment Dimensions Group Inc | 559,325 | Institution | 0.66% | 6,018,337 |
| Vanguard Explorer Fund | 533,079 | Institution | 0.62% | 5,735,930 |
| Vanguard Scottsdale Funds | 511,389 | Institution | 0.60% | 5,502,546 |
| Blackrock Funds | 407,016 | Institution | 0.48% | 4,379,492 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard, VTI ETF | 2,561,366 | Institution | 3.00% | 30,557,096 |
| SPDR, XBI ETF | 2,200,277 | Institution | 2.58% | 23,917,011 |
| iShares, IWM ETF | 1,873,590 | Institution | 2.20% | 20,365,923 |
| Vanguard, VXF ETF | 837,291 | Institution | 0.98% | 9,988,882 |
| iShares, IWO ETF | 699,044 | Institution | 0.82% | 7,521,713 |
| iShares, IBB ETF | 462,940 | Institution | 0.54% | 4,981,234 |
| DFA, DFAS ETF | 445,869 | Institution | 0.52% | 4,846,596 |
| Vanguard, VTWO ETF | 430,676 | Institution | 0.50% | 5,137,965 |
| Schwab, SCHA ETF | 392,538 | Institution | 0.46% | 4,266,888 |
| Avantis, AVUV ETF | 381,882 | Institution | 0.45% | 4,151,057 |
FAQ
Who Owns Monte Rosa Therapeutics (GLUE)?
According to the latest TipRanks data, approximately 33.33% of the company's stock is held by institutional investors, 8.88% is held by insiders, and 57.80% is held by public companies and individual investors.
What percentage of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors?
According to the latest TipRanks data, approximately 33.33% of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors: 17.37% by mutual funds, 15.64% by ETFs and 0.31% by other institutional investors.
What percentage of Monte Rosa Therapeutics (GLUE) stock is held by retail investors?
According to the latest TipRanks data, approximately 57.80% of Monte Rosa Therapeutics (GLUE) stock is held by public companies and individual investors.
Who owns the most shares of Monte Rosa Therapeutics (GLUE)?
BlackRock, Inc. owns the most shares of Monte Rosa Therapeutics (GLUE).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
